Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies
- Written by ACN Newswire - Press Releases
Read more //?#
.
How to ensure your manufacturing business survives international tariff turmoil
Optimising your operations in FY2026 will help you combat the challenges of a volatile trading environment. Up, down, in out…Since the commence...
Why Apptio is Enhancing Visibility into AI and Hybrid Cloud
AI investments have become a strategic priority for business with the mindset that if you're not using AI, you're falling behind. But according to...
Beyond borders: Building a scalable strategy for international hiring
For many Australian businesses, growth increasingly depends on thinking beyond local borders. As wage pressures rise, and specialised talent pool...
The Next Generation of Maritime Sustainable Solutions
As organizations globally seek innovative ways to improve sustainability and their impact on Earth, the American Waterways Operators (AWO), a lead...
Demand for Home Batteries surges as Federal Rebate Kicks In
A leading provider of energy solutions VoltX Energy has seen a 400% increase in demand for home batteries in the past three weeks as people put d...
Why Sport Remains the Safest Bet in an Uncertain World
When Rome was in crisis, its leaders did not retreat to the Senate. They went to the circus. To the chariot races. To the gladiators. Sport was no...
